CAZZANIGA MARINA ELENA

Ruolo: 
Ricercatore a tempo determinato
Settore scientifico disciplinare: 
ONCOLOGIA MEDICA (MED/06)

Pubblicazioni

  • Pizzuti, L., Krasniqi, E., Barchiesi, G., Della Giulia, M., Izzo, F., Sanguineti, G., et al. (2020). Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. INTERNATIONAL JOURNAL OF CANCER, 146(7), 1917-1929. Dettaglio
  • Alberti, P., Cicchiello, F., Riva, F., & Cazzaniga, M. (2020). Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study.. In MEETING PROCEEDINGS.. Dettaglio
  • Scagliotti, A., Grassilli, E., Cazzaniga, M., Capizzi, L., Lavitrano, M., & Cerrito, M. (2020). The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation. EUROPEAN JOURNAL OF CANCER, 138, S26. Dettaglio
  • Alberti, P., Cicchiello, F., Riva, F., Cavaletti, G., & Cazzaniga, M. (2020). A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring. In Abstract book. Dettaglio
  • Krasniqi, E., Pizzuti, L., Barchiesi, G., Sergi, D., Carpano, S., Botti, C., et al. (2020). Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. JOURNAL OF CELLULAR PHYSIOLOGY, 235(11), 7900-7910. Dettaglio